What is the recommended dosing frequency for intravenous L‑arginine L‑aspartate in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dosing Frequency for Intravenous L-Ornithine L-Aspartate (LOLA)

For hepatic encephalopathy in adults, intravenous L-ornithine L-aspartate should be administered as 30 g/day as a continuous infusion over 24 hours. 1

Clinical Context and Administration

The 2020 KASL guidelines for liver cirrhosis specifically recommend 30 g/day of intravenous LOLA for managing overt hepatic encephalopathy 1. This is administered as a single daily dose given continuously over 24 hours, not as divided doses throughout the day.

Evidence for Efficacy

When combined with lactulose, this dosing regimen demonstrated:

  • Lower grades of hepatic encephalopathy within 1-4 days (OR: 2.06-3.04)
  • Shorter duration until symptom recovery (1.92 vs 2.50 days, p=0.002) compared to lactulose alone 1

The mechanism works through ornithine and aspartate serving as substrates to metabolize ammonia to urea and glutamine, thereby lowering plasma ammonia concentrations 1.

Important Distinctions

Do not confuse LOLA with L-arginine, which has entirely different indications and dosing:

  • L-arginine hydrochloride for hyperammonemia in urea cycle disorders is dosed as a 90-minute bolus followed by continuous maintenance over 24 hours 2
  • L-arginine for diagnostic testing (growth hormone stimulation) is given as a single 30-minute infusion 3

Clinical Pearls

  • LOLA is most effective for West-Haven criteria grade 1-2 hepatic encephalopathy 1
  • The continuous 24-hour infusion maintains steady plasma levels for optimal ammonia metabolism
  • Oral LOLA formulations exist but require further study for efficacy in overt hepatic encephalopathy 1
  • Maximum treatment duration is typically 10 days or until clinical improvement 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.